116 related articles for article (PubMed ID: 9581810)
21. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
[TBL] [Abstract][Full Text] [Related]
22. A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation.
Koziolek EJ; Donoghue JF; Bentley JD; Lovrecz G; Dolezal O; Ward CW; Rothacker J; Nice EC; Burgess AW; Hafner M; Johns TG; Adams TE
Growth Factors; 2012 Oct; 30(5):310-9. PubMed ID: 22856597
[TBL] [Abstract][Full Text] [Related]
23. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
24. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
25. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.
Gilmour LM; Macleod KG; McCaig A; Gullick WJ; Smyth JF; Langdon SP
Cancer Res; 2001 Mar; 61(5):2169-76. PubMed ID: 11280782
[TBL] [Abstract][Full Text] [Related]
26. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
27. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
Nishiyama H; Soeda S; Watanabe T; Fujimori K
Fukushima J Med Sci; 2012; 58(1):22-32. PubMed ID: 22790889
[TBL] [Abstract][Full Text] [Related]
28. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Aguilar Z; Akita RW; Finn RS; Ramos BL; Pegram MD; Kabbinavar FF; Pietras RJ; Pisacane P; Sliwkowski MX; Slamon DJ
Oncogene; 1999 Oct; 18(44):6050-62. PubMed ID: 10557094
[TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
Frohnert PW; Stonecypher MS; Carroll SL
Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
[TBL] [Abstract][Full Text] [Related]
30. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
32. Distinct characteristics of heregulin signals mediated by HER3 or HER4.
Weiss FU; Wallasch C; Campiglio M; Issing W; Ullrich A
J Cell Physiol; 1997 Nov; 173(2):187-95. PubMed ID: 9365520
[TBL] [Abstract][Full Text] [Related]
33. Role of heregulin in human cancer.
Breuleux M
Cell Mol Life Sci; 2007 Sep; 64(18):2358-77. PubMed ID: 17530167
[TBL] [Abstract][Full Text] [Related]
34. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
[TBL] [Abstract][Full Text] [Related]
35. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
36. Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay.
Sadick MD; Sliwkowski MX; Nuijens A; Bald L; Chiang N; Lofgren JA; Wong WL
Anal Biochem; 1996 Mar; 235(2):207-14. PubMed ID: 8833330
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase mediates heregulin-induced growth inhibition in human epithelial cells.
Hamburger AW; Yoo JY
Anticancer Res; 1997; 17(3C):2197-200. PubMed ID: 9216687
[TBL] [Abstract][Full Text] [Related]
38. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
39. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Landgraf R; Pegram M; Slamon DJ; Eisenberg D
Biochemistry; 1998 Mar; 37(9):3220-8. PubMed ID: 9485477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
